Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
Alkermes Q2 Sales Up 14 Percent
Alkermes Plc ( NASDAQ:ALKS ) , a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus Wall Street expectations, with diluted earnings per share ( GAAP ) coming in at $0.52, well above ...
Alkermes ( ALKS ) Tops Q2 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +26.83% and +15.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
GSK ( GSK ) Reports Next Week: Wall Street Expects Earnings Growth
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes ( ALKS ) Expected to Beat Earnings Estimates: Should You Buy?
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
Why Is Alkermes Stock Falling On Monday? - Alkermes ( NASDAQ:ALKS )
Alixorexton significantly improved wakefulness and reduced daytime sleepiness at all doses. No serious adverse events reported; most side effects were mild to moderate. Tim Melvin's system has spotted 10X winners like NVIDIA and Matador-see his next 6 picks and the options strategies to multiply ...
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.
How Much Upside is Left in Alkermes ( ALKS ) ? Wall Street Analysts Think 33.19%
The consensus price target hints at a 33.2% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore
EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
ALKS vs. CSLLY: Which Stock Is the Better Value Option?
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Belden ( NYSE:BDC ) , Alkermes ( NASDAQ:ALKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS raised Vistra Corp. VST price target from $160 to $207. UBS analyst William Appicelli maintained a Buy ...
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Cooper Companies ( NASDAQ:COO ) , Alkermes ( NASDAQ:ALKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst David Saxon upgraded the rating for The Cooper Companies, Inc.
Agiloft and PwC UK Form Strategic Collaboration to Transform Contract Lifecycle Management for Enterprises
Partnership empowers enterprise organizations to digitize, optimize, and scale contracting with data-first contract lifecycle management
Should You Invest in the First Trust NYSE Arca Biotechnology ETF ( FBT ) ?
Sector ETF report for ...
Why Is Jazz ( JAZZ ) Up 7.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Aclaris Therapeutics ( NASDAQ:ACRS ) , Alkermes ( NASDAQ:ALKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Ami Fadia initiated coverage on Alkermes plc ALKS with a Buy rating and ...
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Alkermes ( ALKS ) Misses Q1 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of -53.57% and 3.22%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Alkermes Stock We Don't?
Investors need to pay close attention to Alkermes stock based on the movements in the options market lately.
Arcutis Biotherapeutics, Inc. ( ARQT ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Alkermes ( ALKS ) Q1 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680
ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
-Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global ...
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer - Zenas BioPharma ( NASDAQ:ZBIO )
-Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies-
Why Is Alkermes ( ALKS ) Down 6.6% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - Grace Therapeutics ( NASDAQ:GRCE ) , Matinas BioPharma Hldgs ( AMEX:MTNB )
BEDMINSTER, N.J., March 11, 2025 ( GLOBE NEWSWIRE ) -- Matinas BioPharma Holdings, Inc. MTNB today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 ( the "Effective Date" ) .
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
NRXP is expected to provide updates on its pipeline candidates being developed for treating central nervous system disorders when it reports fourth-quarter earnings release.
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.
Alkermes ( ALKS ) Q4 Earnings and Revenues Surpass Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 28.40% and 13.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Alkermes ( ALKS ) Q4 Earnings
Beyond analysts' top -and-bottom-line estimates for Alkermes (ALKS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Schizophrenia Drugs Market Size is Projected to Reach USD 12.33 Billion by 2033, Growing at a CAGR of 5.10%: Straits Research
New York, United States, Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Pharmaceutical interventions for schizophrenia are designed to effectively treat and mitigate the symptoms associated with schizophrenia, a psychiatric disorder characterized by aberrant cognition, affect, and perception.
Qiagen ( QGEN ) Down 1.6% Since Last Earnings Report: Can It Rebound?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx ( RARE ) Down 6.8% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Illumina ( ILMN ) Down 9.3% Since Last Earnings Report: Can It Rebound?
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaxo ( GSK ) Down 6.6% Since Last Earnings Report: Can It Rebound?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Incyte ( INCY ) Up 2.1% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Options Traders Betting on a Big Move in Alkermes ( ALKS ) Stock?
Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.
Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday - Charter Communications ( NASDAQ:CHTR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Canaccord Genuity raised Hims & Hers Health, Inc. HIMS price target from $24 to $28.
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. Shares down.
Alkermes ( ALKS ) Lags Q3 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of -6.41% and 2.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
